BackTable Urology

Are you interested in building an academic niche within global surgery? Dr. Catherine deVries, Professor of Urology and Global Surgery at the University of Utah and founder of International Volunteers in Urology (IVUMed), shares her journey and provides a blueprint for the aspiring academic surgeon. This episode is hosted by Dr. Suzette Sutherland in collaboration with the Society of Women in Urology.---This podcast is supported by:Boston Scientific UroAdvancehttp://bostonscientific.com/uroadvance---SYNPOSISThe episode focuses on Dr. deVries experiences as a groundbreaking woman in the historically male-dominated field of urology. Dr. deVries delves into her landmark contributions to global health, particularly through her work leading IVUMed. She shares her experiences developing sustainable surgical care programs and her academic journey. The conversation also touches on the importance of ethics and public health when conducting surgical missions. The discussion serves as an inspiration for future generations in the field of urology and global health.---TIMESTAMPS00:00 - Introduction02:17 - Dr. DeVries' Academic and Professional Journey04:08 - Experiences as a Woman in Urology14:55 - Pediatric Urology and Global Health21:54 - Founding IVUMed40:34 - Future Directions44:14 - Conclusion---RESOURCESBoston Scientifichttps://www.bostonscientific.com/en-US/medical-specialties/urology/products.htmlSociety of Women in Urologyhttps://swiu.org/home.aspx

We are excited to introduce a new collaboration with the Society of Women in Urology (SWIU)! In this episode of BackTable Urology, guest host Dr. Casey Seideman discusses the impact of SWIU with society leadership Dr. Akanksha Mehta and Dr. Simone Thavaseelan.---This podcast is supported by:Boston Scientific UroAdvancehttp://bostonscientific.com/uroadvance---SYNPOSISThe doctors talk about SWIU's rapid growth, its role in networking and career development for women, and its proven impact across career stages. They highlight the importance of the annual Clinical Mentoring Conference, which provides a unique opportunity for networking and professional development. The conversation also underscores SWIU's inclusivity and efforts for gender-diverse individuals. Looking ahead, Dr. Mehta and Dr. Thavaseelan predict continued growth, innovation, and deeper integration in organized urology.---TIMESTAMPS00:00 - Introduction02:42 - History of SWIU03:29 - Personal Journeys with SWIU07:08 - The Mentoring Conference09:27 - Career Development34:40 - Inclusivity and Male Allyship39:14 - Conclusion---RESOURCESBoston Scientifichttps://www.bostonscientific.com/en-US/medical-specialties/urology/products.htmlSociety of Women in Urologyhttps://swiu.org/home.aspx

Dr. Rana McKay, a medical oncologist from UC San Diego specializing in prostate cancer, passionately discusses the role of androgen deprivation therapy (ADT) in treatment. She delves into the evolution of ADT options and emphasizes personalizing treatment to align with patient goals. The conversation also highlights the important role of PSA PET imaging in management and the shift between continuous and intermittent therapy. Plus, McKay advocates for better patient education to improve outcomes and minimize side effects in this crucial healthcare area.

Are you a private practice urologist looking to build your bladder cancer service lines? In this episode of the BackTable Urology Podcast, Dr. Tom Jayram, urologist from Nashville joins host Dr. Aditya Bagrodia to discuss the latest advancements in non-muscle invasive bladder cancer treatment. The conversation focuses on the unique experiences and practical considerations in managing this complex condition in the community setting.---This podcast is supported by:Ferring Pharmaceuticalshttps://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/---SYNPOSISThe two urologic oncologists share their decision-making process for different therapies such as BCG, gemcitabine-doxorubicin, and Adstiladrin. The conversation also touches on the challenges of integrating new technologies into practice, managing the BCG shortage, and the role of multidisciplinary care. They discuss patient-centered care and the potential for personalized treatment plans. Finally, Dr. Jayram reflects on the lessons he has learned from his own practice, offering a unique insight into the differences between academic and community urology.---TIMESTAMPS00:00 - Introduction04:47 - Community Practice and New Technologies09:59 - Clinical Trials for Bladder Cancer Care15:52 - Patient Referrals29:27 - Exploring New Treatment Options30:46 - Bladder Sparing Strategies32:21 - BCG Treatment and Surveillance47:04 - Implementation of New Therapies54:27 - Future Directions---RESOURCESFerring Pharmaceuticalshttps://www.ferring.com/

If you manage a busy men’s health practice, you may have considered the value of staffing Advanced Practice Providers (APPs). In this episode of BackTable Urology, Dr. Alex Tatem and Kristen Gumpf, PA-C join host Dr. Jose Silva to discuss the role of APPs in men’s health.---This podcast is supported by:Photocurehttps://www.photocure.com/---SYNPOSISTheir discussion highlights the rewarding experience in seeing patients throughout their treatment journey. Dr. Tatem, a men's health specialist with an extensive academic background, emphasizes the value of integrating APPs like Kristen into his practice. Kristen shares her journey, highlighting the importance of continuous learning. Both share their personal stories on the early days and evolution of their partnership. The conversation delves into the dynamics of their successful clinic model, the impact of their work on patient care, and their plans for expanding and educating within the field of men's health.---TIMESTAMPS00:00 - Introduction05:10 - Kristen's Path to Specialization17:42 - Redefining Roles and Responsibilities28:00 - Work-Life Balance31:12 - Office Procedures34:35 - Expanding the Team47:26 - Team Dynamics54:18 - Concluding Thoughts---RESOURCESDr. Alex Tatem’s practice website:https://www.alextatemmd.com/APP Fellowship Program in Indianapolis, Indiana:https://menshealthin.com/training/2024 Prosthetic Urology Institute: Advanced Practice Provider Preceptor Program - Kristen Gumpf, PA-C:https://cvent.me/mNE3ly2024 Prosthetic Urology Institute: Preceptor and Clinic Communications Program with Dr. Alex Tatem:https://cvent.me/1ZKdEq

Dr. Behfar Ehdaie, a urologic oncologist at Memorial Sloan Kettering Cancer Center, discusses innovative strategies for integrating clinical trials into routine urology practice. He shares personal insights on starting pilot trials and engaging stakeholders, emphasizing the importance of patient-centered approaches like two-stage consent to alleviate anxiety. Dr. Ehdaie also tackles the challenges of cumbersome eligibility criteria and advocates for simplifying protocols to enhance trial enrollment and improve outcomes for patients.

Have you checked out the AUA/ASTRO/SUO’s recently released guidelines for salvage therapy in prostate cancer biochemical recurrence? In this episode of the BackTable Urology Podcast, guest Dr. Todd Morgan from the University of Michigan and host Dr. Aditya Bagrodia continue with part two of our series on prostate cancer biochemical recurrence management.---This podcast is supported by:Veracytehttps://www.veracyte.com/decipher---SYNPOSISThe doctors focus on the difficulty in declaring a patient 'cured' and the implications of biochemical recurrence after treatment. Dr. Morgan highlights the importance of PSA in the postoperative setting and explores the role of the Decipher Prostate Genomic Classifier in personalizing treatment. He talks through the latest AUA/ASTRO/SUO consensus on biochemical recurrence guidelines, including the significance of early salvage therapy and the integration of advanced imaging techniques like PSMA PET scans. Further, Dr. Morgan emphasizes the role for multidisciplinary evaluation, patient counseling, and future directions of research to refine treatment options.This discussion underscores the transition from adjuvant to early salvage radiation as a standard practice and considers emerging biomarker strategies to inform treatment decisions.---TIMESTAMPS00:00 - Introduction03:41 - Consensus Biochemical Recurrence Guidelines08:56 - Evolution of Post-Prostatectomy Biochemical Recurrence Management13:24 - Patient Counseling and Risk of Recurrence17:42 - PSMA PET Scans20:44 - Postoperative PSA Monitoring28:35 - The Role of Radiation31:56 - Hormone Therapy39:00 - Salvage Lymphadenectomy46:30 - Future Directions and Concluding Thoughts---RESOURCESVeracytehttps://www.veracyte.com/Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline (2024)https://www.auanet.org/guidelines-and-quality/guidelines/salvage-therapy-for-prostate-cancer

Dr. Shawn West, a Urologist at McIver Clinic in Florida, dives into contemporary BPH treatment strategies. He discusses the shift from medication-focused care to prioritizing long-term bladder health and individualized treatments. Key highlights include the use of modern techniques like UroLift and Aquablation, as well as the importance of patient engagement in decision-making. Dr. West further emphasizes the significance of the International Prostate Symptom Score in assessing urinary symptoms and the value of post-treatment expectations for better recovery outcomes.

Dr. Betsy Koehne specializes in bladder cancer at the University of Wisconsin, while Dr. Amir Salmasi is known for his impactful work at UC San Diego. They discuss contemporary strategies for managing low and intermediate-risk bladder cancer, emphasizing personalized care and effective patient communication. The conversation highlights the importance of understanding patient distress, advancements in intravesical therapies, and ongoing clinical trials aimed at improving outcomes. They also delve into the intricacies of postoperative surveillance and the role of pathology in treatment decisions.

Recent research is changing how we manage low risk prostate cancer. In this BackTable Urology Podcast episode, Dr. Dan Lin, a urologist at the University of Washington, walks through contemporary diagnosis, surveillance, and management of Grade Group 2 prostate cancer with host Dr. Aditya Bagrodia.---This podcast is supported by:Veracytehttps://www.veracyte.com/decipher---SYNPOSISThe doctors delve into real-world implementation of active surveillance, alongside the use of advanced diagnostics, biopsy methods, and personalized care plans. The conversation highlights the Canary Prostate Active Surveillance Study (PASS) and the prognostic role of biomarkers and genomic testing. Dr. Lin and Dr. Bagrodia also discuss how lifestyle factors such as diet impact cancer progression and how patients can be empowered to manage their disease. Strategies for transitioning patients off surveillance are highlighted. Finally, the two experts discuss insights from recent clinical trials like PIVOT, PROTECT, and SPCG and how they’re impacting prostate cancer management.---TIMESTAMPS00:00 - Introduction02:54 - Active Surveillance and Canary PASS Data12:02 - Biopsy Considerations19:44 - Active Surveillance Protocols26:58 - Patient Concerns and Risk Reduction30:52 - Transitioning Off Surveillance33:39 - Grade Group 2: Treatment vs. Monitoring46:24 - Surgical Considerations and Node Dissection49:25 - Future Directions---RESOURCESVeracytehttps://www.veracyte.com/